Clobetasol shortage: What providers and prescribers need to know in 2026

Clobetasol Propionate Supply Disruption: Provider Briefing for 2026

Clobetasol Propionate 0.05% — the benchmark Class I (super-potent) topical corticosteroid — is experiencing supply constraints in 2026. This article provides prescribers and clinical staff with actionable information to maintain continuity of care for patients with severe corticosteroid-responsive dermatoses.

Current Supply Status

The FDA drug shortage database indicates at least one manufacturer has discontinued production of Clobetasol Propionate Ointment 0.05%. Supply disruptions have expanded to affect other formulations intermittently, though the degree varies by region and distributor.

Formulation Availability Summary

FormulationCurrent AvailabilityClinical NotesOintment 0.05%Limited — manufacturer exitMost affected; consider cream or gel substitutionCream 0.05%Generally availableLower occlusion than ointment; may require occlusive dressing for equivalent efficacy in thick plaquesGel 0.05%Generally availableGood for hairy areas; drying vehicleFoam 0.05% (Olux)IntermittentExcellent for scalp and hair-bearing areas; higher costSolution 0.05%AvailableScalp formulationLotion 0.05%AvailableSuitable for larger body surface areasSpray 0.05%VariableRegional differences in stockShampoo 0.05%AvailableScalp psoriasis; apply, lather, wait 15 min, rinseCream 0.025% (Impoyz)AvailableLower concentration; may suit milder presentations or maintenance

Therapeutic Alternatives Within Class I

When Clobetasol is unavailable, the following Class I (super-potent) topical corticosteroids offer equivalent or near-equivalent efficacy:

Halobetasol Propionate 0.05% (Ultravate)

• Most pharmacologically similar to Clobetasol
• Available as cream, ointment, and lotion
• Same treatment duration limitations (2 weeks continuous, ≤50 g/week)
• Generic widely available

Betamethasone Dipropionate 0.05%, Augmented (Diprolene)

• Class I in ointment and gel formulations; Class II in cream
• Augmented formulation is critical — standard Betamethasone Dipropionate is Class III-V depending on vehicle
• Prescribe specifically as "Betamethasone Dipropionate, augmented" to ensure correct potency
• Generic available

Diflorasone Diacetate 0.05% (ApexiCon E)

• Class I in ointment; Class II in cream
• Less commonly stocked; check availability before prescribing

Step-Down Alternatives (Class II)

For patients whose disease severity permits, or when no Class I alternatives are available:

• Fluocinonide 0.05% (Vanos): Widely available, affordable generic. Cream, ointment, gel, solution.
• Desoximetasone 0.25% (Topicort): Cream, ointment, gel, spray. Good availability.
• Halcinonide 0.1% (Halog): Cream, ointment. Less commonly used but effective.

Non-Steroidal Adjuncts and Alternatives

Consider these for steroid-sparing strategies or when corticosteroids are contraindicated:

• Calcipotriene (Dovonex): Vitamin D analog for plaque psoriasis. Can be combined with mid-potency steroids.
• Calcipotriene/Betamethasone Dipropionate (Enstilar, Wynzora): Fixed combination products for psoriasis.
• Tacrolimus 0.1% (Protopic): Topical calcineurin inhibitor for eczema, especially facial/intertriginous involvement.
• Roflumilast cream 0.3% (Zoryve): PDE4 inhibitor for plaque psoriasis — newer agent, steroid-free.
• Tapinarof 1% (Vtama): Aryl hydrocarbon receptor agonist for plaque psoriasis — another steroid-free option.

Prescribing Strategies During the Shortage

1. Specify "substitution permitted" on prescriptions. This allows pharmacists to dispense a different formulation (cream vs. ointment) if one is unavailable, reducing callbacks.
2. Write for the active ingredient, not the brand. Prescribing "Clobetasol Propionate 0.05% cream" rather than "Temovate" maximizes the chance of filling.
3. Consider writing backup prescriptions. Provide a primary prescription for Clobetasol and discuss with the patient that if it can't be filled, you can quickly send an alternative.
4. Educate patients on formulation equivalence. Many patients don't realize that cream, ointment, and gel all contain the same active ingredient. Explaining this can reduce anxiety about switching.
5. Leverage MedFinder for patient referrals. Direct patients to MedFinder for Providers or have your staff use it to locate pharmacies with current stock. This tool checks real-time inventory and can save significant time.
6. Document shortage-related changes. Note in the chart when a therapeutic substitution is made due to shortage. This supports continuity and reduces confusion at future visits.

Patient Communication Recommendations

Patients may be anxious or frustrated when their medication is unavailable. Consider these talking points:

• "The active ingredient is the same in all formulations — we're just changing the vehicle."
• "There are other super-potent steroids that work very similarly to Clobetasol."
• "This shortage isn't permanent — we'll switch you back when supply improves."
• "You can use MedFinder to check which pharmacies near you have it in stock right now."

For patient-facing resources, you can share these articles:

• Clobetasol shortage update for patients
• Alternatives to Clobetasol
• How to find Clobetasol in stock

Monitoring and Follow-Up

When switching patients to alternative agents:

• Schedule follow-up within 2-4 weeks to assess response
• Monitor for HPA axis suppression if patients have been on high-potency steroids long-term
• Reassess the need for super-potent therapy — the shortage may be an opportunity to step down therapy in patients with well-controlled disease
• Document patient education about the shortage and the rationale for any changes

Resources for Providers

• MedFinder for Providers — real-time pharmacy stock checking
• How to help your patients find Clobetasol in stock: A provider's guide
• How to help patients save money on Clobetasol
• FDA Drug Shortage Database — accessdata.fda.gov
• ASHP Drug Shortage Resource Center — ashp.org